Simply Wall St.
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback?
📊
AI Sentiment
Positive
7/10
- Home
- MLYS
as of 03-23-2026 2:23pm EST
$23.74
$0.16
-0.67%
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 2.4B | IPO Year: | 2023 |
| Target Price: | $48.67 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | 37.43 |
| 52 Week Low/High: | $10.44 - $47.65 | Next Earning Date: | 03-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -10.44 | Index: | N/A |
| Free Cash Flow: | -142431000.0 | FCF Growth: | N/A |
AI-Powered MLYS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 76.74%
76.74%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Mar 17, 2026
Avg Cost/Share
$25.65
Shares
417
Total Value
$10,696.05
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Mar 13, 2026
Avg Cost/Share
$27.03
Shares
14,058
Total Value
$369,225.45
Owned After
76,140
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Mar 12, 2026
Avg Cost/Share
$27.37
Shares
6,348
Total Value
$173,747.93
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Mar 9, 2026
Avg Cost/Share
$26.84
Shares
2,171
Total Value
$58,269.64
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Feb 17, 2026
Avg Cost/Share
$27.59
Shares
417
Total Value
$11,505.03
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Feb 9, 2026
Avg Cost/Share
$30.21
Shares
2,171
Total Value
$65,585.91
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Jan 20, 2026
Avg Cost/Share
$32.10
Shares
416
Total Value
$13,353.60
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Jan 14, 2026
Avg Cost/Share
$32.61
Shares
11,367
Total Value
$370,644.91
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Jan 13, 2026
Avg Cost/Share
$32.75
Shares
7,709
Total Value
$252,469.75
Owned After
76,140
SEC Form 4
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Jan 12, 2026
Avg Cost/Share
$32.32
Shares
6,348
Total Value
$205,143.24
Owned After
76,140
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Rodman David Malcom | MLYS | Chief Medical Officer | Mar 17, 2026 | Sell | $25.65 | 417 | $10,696.05 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Mar 13, 2026 | Sell | $27.03 | 14,058 | $369,225.45 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Mar 12, 2026 | Sell | $27.37 | 6,348 | $173,747.93 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Mar 9, 2026 | Sell | $26.84 | 2,171 | $58,269.64 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Feb 17, 2026 | Sell | $27.59 | 417 | $11,505.03 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Feb 9, 2026 | Sell | $30.21 | 2,171 | $65,585.91 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Jan 20, 2026 | Sell | $32.10 | 416 | $13,353.60 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Jan 14, 2026 | Sell | $32.61 | 11,367 | $370,644.91 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Jan 13, 2026 | Sell | $32.75 | 7,709 | $252,469.75 | 76,140 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Jan 12, 2026 | Sell | $32.32 | 6,348 | $205,143.24 | 76,140 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 12, 2026 · 100% conf.
AI Prediction SELL
1D
-5.92%
$25.39
Act: -2.82%
5D
-8.12%
$24.80
20D
-8.50%
$24.70
Price: $26.99 Prob +5D: 0% AUC: 1.000
0001933414-26-000054
mlys-20260312false000193341400019334142026-03-122026-03-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2026
MINERALYS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4161484-1966887 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
150 N. Radnor Chester Rd., Suite F200 Radnor, PA 19087
(Address of principal executive offices) (Zip Code)
(888) 378-6240
(Registrant’s telephone number, include area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share
MLYS
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 12, 2026, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1 Press Release Issued on March 12, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 12, 2026MINERALYS THERAPEUTICS, INC.
By:/s/ Adam Levy
Name:Adam Levy
Title:Chief Financial Officer and Secretary
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 10, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 10, 2025 · 100% conf.
AI Prediction SELL
1D
-7.40%
$41.21
Act: +5.87%
5D
-9.06%
$40.47
Act: -0.54%
20D
-7.38%
$41.21
Act: -17.46%
Price: $44.50 Prob +5D: 0% AUC: 1.000
0001933414-25-000139
mlys-20251110false000193341400019334142025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2025
MINERALYS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4161484-1966887 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
150 N. Radnor Chester Road, Suite F200 Radnor, Pennsylvania 19087
(Address of principal executive offices) (Zip Code)
(888) 378-6240
(Registrant’s telephone number, include area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share
MLYS
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 10, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1 Press Release Issued on November 10, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 10, 2025MINERALYS THERAPEUTICS, INC.
By:/s/ Adam Levy
Name:Adam Levy
Title:Chief Financial Officer and Secretary
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 12, 2025
0001933414-25-000088
mlys-20250812false000193341400019334142025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2025
MINERALYS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4161484-1966887 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
150 N. Radnor Chester Road, Suite F200 Radnor, Pennsylvania 19087
(Address of principal executive offices) (Zip Code)
(888) 378-6240
(Registrant’s telephone number, include area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share
MLYS
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1 Press Release Issued on August 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 12, 2025MINERALYS THERAPEUTICS, INC.
By:/s/ Adam Levy
Name:Adam Levy
Title:Chief Financial Officer and Secretary
Latest Mineralys Therapeutics Inc. News
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
Compare MLYS vs Leading Stocks
See how MLYS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.